A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Inclusion Criteria:

- Definitive diagnosis of unresectable locally advanced or metastatic RCC with
clear-cell histology and/or a component of sarcomatoid carcinoma, with no prior
treatment in the metastatic setting

- Evaluable Memorial Sloan Kettering Cancer Center risk score

- Measurable disease, as defined by RECIST v1.1

- Karnofsky performance status greater than or equal to 70%

- Adequate hematologic and end-organ function prior to randomization

Exclusion Criteria:

Disease-Specific Exclusions:

- Radiotherapy for RCC within 14 days prior to treatment

- Active central nervous system disease

- Uncontrolled pleural effusion, pericardial effusion, or ascites

- Uncontrolled hypercalcemia

- Any other malignancies within 5 years except for low-risk prostate cancer or those
with negligible risk of metastasis or death

General Medical Exclusions:

- Life expectancy less than 12 weeks

- Participation in another experimental drug study within 4 weeks prior to treatment

- Pregnant or lactating women

- Known hypersensitivity to any component of atezolizumab or other study medication

- History of autoimmune disease except controlled, treated hypothyroidism or type I
diabetes mellitus

- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
pneumonitis, or idiopathic pneumonitis

- Positive human immunodeficiency virus test

- Active or chronic hepatitis B or C

- Severe infections within 4 weeks prior to treatment

- Exposure to oral or IV antibiotics within 2 weeks prior to treatment

- Live attenuated vaccines within 4 weeks prior to treatment (for influenza vaccination
participants must agree not to receive live, attenuated influenza vaccine within 4
weeks prior to treatment, during treatment or within 5 months following the last dose)

- Significant cardiovascular disease

- Prior allogeneic stem cell or solid organ transplantation

Exclusion Criteria Related to Medications:

- Prior treatment with cluster of differentiation 137 agonists, anti-cytotoxic
T-lymphocyte associated protein-4, anti-programmed death (PD)-1, or anti-PD-L1
therapeutic antibody or pathway-targeting agents

- Treatment with immunostimulatory agents for non-malignant conditions within 6 weeks or
immunosuppressive agents within 2 weeks prior to treatment

Bevacizumab- and Sunitinib-Specific Exclusions:

- History of hypertensive crisis or hypertensive encephalopathy

- Baseline electrocardiogram showing corrected QT interval greater than 460 milliseconds